Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Subscribe To Our Newsletter & Stay Updated
